483
Allergan, PLC.Allergan, PLC. – FDA 483, Apr 11, 2019
Record Details
An FDA inspection of Allergan, PLC.'s corporate headquarters in Madison, NJ, revealed significant deficiencies in their Risk Evaluation and Mitigation Strategy (REMS) program for opioid analgesics. The firm failed to properly dispense the required Medication Guide and did not adequately maintain its REMS program website and support systems. These issues indicate a failure to ensure critical safety information is accessible to patients and healthcare providers.
View Company Profile
ID · ef413229-6a75-4f53-9264-6de0bad68326
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.